TY  - JOUR
AU  - Ibanez-Costa, Alejandro
AU  - Rivero-Cortes, Esther
AU  - Vazquez-Borrego, Mari C.
AU  - Gahete, Manuel D.
AU  - Jimenez-Reina, Luis
AU  - Venegas-Moreno, Eva
AU  - de la Riva, Andres
AU  - Angel Arraez, Miguel
AU  - Gonzalez-Molero, Inmaculada
AU  - Schmid, Herbert A.
AU  - Maraver-Selfa, Silvia
AU  - Gavilan-Villarejo, Inmaculada
AU  - Antonio Garcia-Arnes, Juan
AU  - Japon, Miguel A.
AU  - Soto-Moreno, Alfonso
AU  - Galvez, Maria A.
AU  - Luque, Raul M.
AU  - Castano, Justo P.
PY  - 2016
DO  - 10.1530/JOE-16-0332
SN  - 0022-0795
UR  - http://hdl.handle.net/10668/19187
T2  - Journal of endocrinology
AB  - Somatostatin analogs (SSA) are the mainstay of pharmacological treatment for pituitary adenomas. However, some patients escape from therapy with octreotide, a somatostatin receptor 2 (sst2)-preferring SSA, and pasireotide, a novel multi-sst-preferring...
LA  - en
PB  - BioScientifica
KW  - Growth-hormone
KW  - Receptor subtypes
KW  - Quantitative-analysis
KW  - Aggressive features
KW  - Medical-treatment
KW  - Cushings-disease
KW  - Acth release
KW  - Adenomas
KW  - Pituitary
KW  - Pituitary adenoma
KW  - Somatostatin
KW  - Gene expression
KW  - Cell signaling
KW  - Somatostatin analog som230
KW  - Gene-expression levels
TI  - Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
TY  - research article
VL  - 231
ER  -